Millennium Management
ONCT

Millennium Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Millennium Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-61,205
Closed -$80.8K – 6684
2024
Q3 		$80.8K Sell
61,205
-41,731
-41% -$202K ﹤0.01% 5617
2024
Q2 		$782K Sell
102,936
-159
-0.2% -$1.37K ﹤0.01% 4282
2024
Q1 		$928K Buy
103,095
+300
+0.3% +$2.64K ﹤0.01% 4357
2023
Q4 		$1.1M Buy
102,795
+20,433
+25% +$147K ﹤0.01% 4074
2023
Q3 		$500K Buy
82,362
+118
+0.1% +$831 ﹤0.01% 4662
2023
Q2 		$567K Buy
82,244
+7,467
+10% +$49.2K ﹤0.01% 4449
2023
Q1 		$1.17M Buy
74,777
+16,790
+29% +$330K ﹤0.01% 3941
2022
Q4 		$1.16M Buy
57,987
+28,742
+98% +$572K ﹤0.01% 4017
2022
Q3 		$522K Sell
29,245
-35,561
-55% -$763K ﹤0.01% 4941
2022
Q2 		$1.44M Buy
64,806
+42,300
+188% +$943K ﹤0.01% 4033
2022
Q1 		$626K Buy
22,506
+2,093
+10% +$76.2K ﹤0.01% 4936
2021
Q4 		$927K Buy
20,413
+4,480
+28% +$301K ﹤0.01% 4480
2021
Q3 		$1.33M Buy
15,933
+8,225
+107% +$680K ﹤0.01% 4371
2021
Q2 		$732K Sell
7,708
-12,057
-61% -$1.43M ﹤0.01% 4957
2021
Q1 		$3.29M Buy
19,765
+3,908
+25% +$517K ﹤0.01% 3036
2020
Q4 		$1.55M Buy
15,857
+14,086
+795% +$891K ﹤0.01% 3429
2020
Q3 		$60 Sell
1,771
-1,357
-43% -$66.5K ﹤0.01% 4284
2020
Q2 		$178K Sell
3,128
-136
-4% -$7.67K ﹤0.01% 3875
2020
Q1 		$191K Sell
3,264
-144
-4% -$10.7K ﹤0.01% 3409
2019
Q4 		$269K Sell
3,408
-1,503
-31% -$156K ﹤0.01% 3719
2019
Q3 		$491K Buy
+4,911
New +$503K ﹤0.01% 3272
2019
Q1 		– Sell
-106
Closed -$12K – 4421
2018
Q4 		$12K Sell
106
-1,365
-93% -$273K ﹤0.01% 3682
2018
Q3 		$323K Buy
1,471
+1,323
+894% +$3.17M ﹤0.01% 3452
2018
Q2 		$318K Sell
148
-723
-83% -$1.83M ﹤0.01% 3365
2018
Q1 		$2.17M Buy
871
+450
+107% +$1M ﹤0.01% 2262
2017
Q4 		$749K Buy
+421
New +$610K ﹤0.01% 2881
2017
Q2 		– Sell
-445
Closed -$305K – 3974
2017
Q1 		$305K Sell
445
-194
-30% -$142K ﹤0.01% 3036
2016
Q4 		$472K Buy
639
+623
+3,894% +$666K ﹤0.01% 2698
2016
Q3 		$17K Buy
+16
New +$14K ﹤0.01% 3219
2015
Q1 		– Sell
-36
Closed -$37K – 4229
2014
Q4 		$37K Buy
36
+8
+29% +$7.14K ﹤0.01% 3839
2014
Q3 		$29K Buy
28
+7
+33% +$10.3K ﹤0.01% 3626
2014
Q2 		$40K Buy
+21
New +$41.6K ﹤0.01% 3309
2013
Q3 		– Sell
-39
Closed -$360K – 3644
2013
Q2 		$360K Buy
+39
New +$301K ﹤0.01% 2494

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Millennium Management's ONCT Position: Q4 2024 in Review

Millennium Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 61,205 shares — an estimated $80.8K sold.

Millennium Management first reported a position in ONCT in Q2 2013 and held it in 33 quarters. The position peaked at $3.29M in Q1 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Millennium Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Millennium Management sold 61,205 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $80.8K.
  • Millennium Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 33 quarters.
  • Millennium Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.29M in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.